Mira Pharmaceuticals' MIRA-55 shows pain relief comparable to Celebrex in rat study

• Mira Pharmaceuticals’ oral MIRA-55 matched Celebrex’s pain relief at higher doses in a 21-day chronic inflammatory pain study involving 72 rats.
• All tested doses significantly reduced mechanical and thermal pain hypersensitivity versus vehicle control (p < 0.001).
• Pain relief persisted throughout daily dosing without observed tolerance, with comparable effects in male and female animals.
• Paw swelling declined by a similar magnitude to Celebrex; no adverse clinical signs or deaths were reported.
• An investigational new drug submission is planned for the first quarter of 2027, subject to remaining preclinical and regulatory work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-048022), on October 22, 2026, and is solely responsible for the information contained therein.